Oprah reveals she stopped GLP-1s for a year and regained 20 pounds

Oprah Winfrey says she stepped away from GLP-1 medication after roughly six months to see whether she could maintain her weight loss without it, gained back about 20 pounds over the following 12 months, and then resumed treatment. She told People in an exclusive interview that she now views the medication as "going to be a lifetime thing" ^[1].

Winfrey has been one of the most visible public figures discussing GLP-1 use, and her account of stopping and restarting adds a rarely told middle chapter to celebrity weight-loss stories. Fox News included her among the public figures who spoke about significant weight loss during 2025 ^[2].

What she described

The sequence, as she described it to People, was straightforward: about six months on the medication, then a deliberate pause to test whether diet and exercise alone would hold the result, then roughly 20 pounds of regain across a year, then a return to treatment and the conclusion that ongoing use is likely permanent for her ^[1].

Several details are not available in the sources reviewed here. The full People interview text was not accessible, so specifics such as which medication she used — semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), or another drug in the class — the dose, the exact dates, and her total weight change are not documented in what we can cite ^[1][2]. Readers should treat the 20-pound figure and the roughly six-month and 12-month timeframes as her own account rather than clinical data.

It is also worth saying plainly what a single personal story can and cannot show. One person's experience does not establish how often regain happens, how large it typically is, or who is most likely to hold weight off after stopping. Trial evidence on weight regain after discontinuation exists in the medical literature, but none of it appears in the sources for this story, so no percentages or averages are cited here.

Why it matters for patients

The practical question behind Winfrey's story — what happens if I stop? — is one of the most common concerns among people considering or currently taking these drugs. Her account is a high-profile example of the regain-after-stopping pattern, described by someone with essentially unlimited access to trainers, chefs and medical care ^[1].

That framing has financial consequences. If a medication is treated as long-term or lifelong therapy rather than a short course, the relevant cost is not a few months of prescriptions but years of them, including whatever insurance covers, what a plan requires for continued authorization, and what happens if coverage changes or a job changes. Whether treatment is indefinite also shapes conversations about side effects, monitoring and what "success" means over time.

There is a second, less measurable effect. Public stories that show only the loss can make regain feel like a personal failure. Winfrey's description of trying to maintain on her own, not succeeding, and going back on the medication reframes that as a feature of how the treatment works for her rather than a lapse in willpower ^[1].

None of this says what any individual's course should look like. Decisions about starting, pausing or stopping a GLP-1 involve the reason it was prescribed, other health conditions, side effects and cost, and those belong in a conversation with a prescribing clinician.

What happens next

People published the interview at the end of December 2025 ^[1]. There is no indication in the sources of a follow-up interview, a documentary, or any further disclosure from Winfrey about her treatment. Whether she names the specific medication, or shares more detail about her total weight change and how long she has now been back on treatment, is not known from these sources.

For readers tracking the broader question, the more useful information will come from published research on maintenance and discontinuation rather than from celebrity accounts. That evidence is not part of this report.